Industry News

Biotechnology Industry News

Gary Gibbons, M.D., is retiring as…

January 13th, 2026|FierceBiotech|

Gary Gibbons, M.D., is retiring as National Heart, Lung and Blood Institute director, adding to the extensive churn at the top of the National Institutes of Health. The departure will mean 15 of the NIH’s

SAN FRANCISCO—The deal-hungry…

January 13th, 2026|FierceBiotech|

SAN FRANCISCO—The deal-hungry Danish pharma is largely sticking to its metabolic roots as it seeks out new innovation to bring into its drug development machine.

It’s been a subdued—albeit…

January 13th, 2026|FierceBiotech|

It’s been a subdued—albeit sunny—start to healthcare’s biggest conference in San Francisco. For Takeda's R&D head Andy Plump, M.D., Ph.D., the slower pace of the annual J.P. Morgan Healthcare Conference has been offset by the industry's

AbbVie has made no secret of the…

January 12th, 2026|FierceBiotech|

AbbVie has made no secret of the fact that it's taken an interest in the hotly contested PD-1xVEGF bispecific space. Now, the Big Pharma has paid $650 million to make its ambitions in this arena

A phase 3 rheumatoid arthritis…

January 12th, 2026|FierceBiotech|

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor has hit its primary endpoint, boosting the prospects of a candidate designed to avoid the adverse events caused by existing drugs.

Eikon Therapeutics is planning to…

January 12th, 2026|FierceBiotech|

Eikon Therapeutics is planning to become the second biotech to go public in 2026 in another sign that the public markets are looking increasingly attractive to drug developers.

Eli Lilly and Nvidia, two primary…

January 9th, 2026|FierceBiotech|

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon with biology through AI-powered drug development.

The Trump administration spent…

January 9th, 2026|FierceBiotech|

The Trump administration spent 2025 taking a sledgehammer to science, obliterating funding and reshaping agencies like the FDA and the National Institutes of Health through layoffs and restrictive new policies. In a new letter, Noubar

Madrigal paid Pfizer $50 million…

January 9th, 2026|FierceBiotech|

Madrigal paid Pfizer $50 million for the rights to a DGAT2i inhibitor that the biopharma intends to combine with its approved liver disease drug Rezdiffra.

Roche has got in on the B7-H3…

January 9th, 2026|FierceBiotech|

Roche has got in on the B7-H3 action, agreeing to $570 million in near-term payments to existing partner MediLink Therapeutics for an ADC targeting the immune checkpoint protein.

After netting a $361 million…

January 8th, 2026|FierceBiotech|

After netting a $361 million series C funding round in October, 2024 Fierce 15 winner Tubulis has reeled in a big name for its chief medical officer spot in Charles Fuchs, M.D. Fuchs is a

The life sciences world is once…

January 8th, 2026|FierceBiotech|

The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026. Fierce Biotech is here tracking the biggest deals, data drops and industry shifts as

After unsheathing just a few…

January 8th, 2026|FierceBiotech|

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than Genentech’s Vabysmo for patients with diabetic macular edema (DME) in an early-stage study.